Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Blow to Ranbaxy Drug Research Plans (India)

This article was originally published in PharmAsia News

Executive Summary

Medicines for Malaria Venture (MMV), a World Health Organization agency, has announced that it is pulling out of its partnership with Ranbaxy Laboratories Ltd. to develop a anti-malarial drug. Since 2003, Ranbaxy, India's second-largest drug manufacturer, has been working with MMV to create a man-made version of Arterolane, a Chinese herbal remedy for malaria. Ranbaxy recently completed Phase II clinical trials on Arterolane. MMV had also performed several studies on the drug. MMV representatives say the decision to end their involvement in the project was the result of Arterolane's less-than-stellar performance in those trials. Despite the setback, Ranbaxy has said it will continue to develop the new drug and hope to have it ready to market by 2011. (Click here for more

You may also be interested in...

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

SynOx Seeks Solution For TGCT With Roche Antibody

The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.

Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts